JF
BTAI icon

Jump Financial’s BioXcel Therapeutics BTAI Stock Holding History

Jump Financial’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,625
Closed -$307K – 1593
2022
Q3 		$307K Buy
1,625
+295
+22% +$68.5K 0.01% 1136
2022
Q2 		$281K Buy
+1,330
New +$280K 0.01% 1101
2021
Q4 		– Sell
-498
Closed -$242K – 1394
2021
Q3 		$242K Sell
498
-27
-5% -$11.9K 0.02% 771
2021
Q2 		$244K Sell
525
-181
-26% -$98.7K 0.02% 762
2021
Q1 		$488K Buy
+706
New +$568K 0.05% 407
2020
Q4 		– Sell
-645
Closed -$448K – 961
2020
Q3 		$448K Buy
+645
New +$484K 0.09% 361

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Jump Financial's BTAI Position: Q4 2022 in Review

Jump Financial sold out of BioXcel Therapeutics (BTAI) in Q4 2022, closing a stake of 1,625 shares — an estimated $307K sold.

Jump Financial first reported a position in BTAI in Q3 2020 and held it in 6 quarters. The position peaked at $488K in Q1 2021. 83 funds tracked by Wall St. Rank hold BTAI as of Q4 2022.

  • Jump Financial reported no remaining BioXcel Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Jump Financial sold 1,625 BioXcel Therapeutics shares in Q4 2022, an estimated $307K.
  • Jump Financial first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 6 quarters.
  • Jump Financial's BioXcel Therapeutics position peaked at $488K in Q1 2021.
  • 83 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2022.

Based on Jump Financial's 13F filing for Q4 2022, filed 14 Feb 2023.